News for AbbVie Inc. (ABBV34.SA)

AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash. The acquisition will expand AbbVie’s product pipeline, particularly in experimental treatments for autoimmune diseases. Capstan Therapeutics […]

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

Key Highlights: AbbVie (ABBV) revises Q2 earnings forecast due to significant expenses. Wall Street analysts suggest a price target increase of 11.82%.

GOOGL, ABBV, and DIS face distinct headwinds, but cloud strength, immunology growth, and parks momentum support long-term investor interest.

Looking for the latest dividend stock opportunities in July 2025? Click to read these top dividend stock picks to bulk up your income.

AbbVie Inc. (ABBV) shares increased 0.49% to $183.20 in early trading, driven by its acquisition of Capstan Therapeutics for up to $2.1 billion in cash, aimed at enhancing its autoimmune disease treatment portfolio. The deal includes Capstan’s CPTX2309, a Phase 1 anti-CD19 CAR-T therapy for B cell-mediated autoimmune diseases, and…

AbbVie Inc. (NYSE:ABBV) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, the “Elahere Market Opportunities and Strategies to 2034” report was added to ResearchAndMarkets.com’s offering. It stated that the global market for Elahere, which is a treatment primarily for ovarian cancer, is anticipated to experience rapid […]

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices. What Happened: The clash, unfolding as of Friday, has ...

AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King, having raised its dividend for 52 straight years. That kind of track record makes a dividend cut highly unlikely, as it would break the streak and potentially take decades to regain entry […]

Summary On June 20, 2025, AbbVie Inc (ABBV) announced that its board of directors has declared a quarterly cash dividend of $1.64 per share, payable on August 1

PR NewswireNORTH CHICAGO, Ill., June 20, 2025 NORTH CHICAGO, Ill., June 20, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today d

Key Takeaways: AbbVie (ABBV) maintains a robust dividend strategy with a 3.54% forward yield. Analysts project an average price target of $211.65, sugges

Quarterly dividend of $1.64 per share emphasizes consistent shareholder returns. AbbVie (ABBV) boasts a 310% dividend growth since 2013, highlighting ro

India's Department of Pharmaceuticals found AbbVie Healthcare India sponsored ₹1.91 crore in international trips for 30 doctors, violating marketing practice codes. These trips to Paris and Monaco for an 'anti-ageing conference' raise ethical and tax concerns. Despite the breach, the DoP refuses to disclose the doctors' names, citing privacy, sparking criticism for shielding violators and undermining transparency.

AbbVie's migraine drug atogepant achieves primary endpoint in a pivotal trial, reducing migraine frequency. Wall Street analysts forecast an average pri

Summary On June 18, 2025, AbbVie Inc (ABBV) announced promising results from its Phase 3 TEMPLE study, which evaluated the efficacy, safety, and tolerability of

PR NewswireNORTH CHICAGO, Ill., June 18, 2025 TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safe